Genkyotex has begun a multinational Phase II clinical study of GKT137831 in patients with diabetic nephropathy. GKT137831 is a first-in-class inhibitor targeting NOX1 and NOX4 enzymes, both of which play a key role in the development of diabetic complications and chronic kidney disease in particular. In Phase I studies in more than 100 subjects, GKT137831 was found to be safe and well tolerated when administered orally once and twice daily. The placebo controlled, double-blind, randomized Phase...